BRAF and non-small cell lung carcinoma: Despite the evidence, although limited in some cases, of the clinical success of BRAF inhibitor monotherapy in BRAFV600E-mutant NSCLC, most patients developed adaptive resistance, resulting in reactivation of the MAPK pathway [71,72,73,74].